Related Experiment Video
Updated: Nov 16, 2025
Isolation, Culture, and Characterization of Primary Dermal Fibroblasts from Human Keloid Tissue
Published on: July 28, 2023
Inhibitory Effect of the LY2109761 on the Development of Human Keloid Fibroblasts
Xiuxia Wang1, Chuan Gu1, Feng Shang2
1Department of Plastic and Reconstructive Surgery, Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, China.
Abstract:
Keloids are scars characterized by abnormal proliferation of fibroblasts and overproduction of extracellular matrix components including collagen. We previously showed that LY2109761, a transforming growth factor- (TGF-) β receptor inhibitor, suppressed the secretion of matrix components and slowed the proliferation of fibroblasts derived from human hypertrophic scar tissue. However, the exact mechanism underlying this effect remains unclear. Here, we replicated the above results in keloid-derived fibroblasts and show that LY2109761 promoted apoptosis, decreased the phosphorylation of Smad2 and Smad3, and suppressed TGF-β1. These results suggest that the development and pathogenesis of keloids are positively regulated by the Smad2/3 signaling pathway and the upregulation of TGF-β1 receptors. LY2109761 and other inhibitors of these processes may therefore serve as therapeutic targets to limit excessive scarring after injury.
Insights
LY2109761, a transforming growth factor-beta (TGF-β) receptor inhibitor, inhibits keloid fibroblast proliferation and promotes apoptosis. This suggests TGF-β1 signaling is key in keloid development, making inhibitors potential therapeutic targets for excessive scarring.
Area of Science:
- Dermatology
- Cell Biology
- Molecular Biology
Background:
- Keloids result from abnormal fibroblast proliferation and excessive extracellular matrix production.
- Transforming growth factor-beta (TGF-β) signaling is implicated in keloid pathogenesis.
- Previous studies indicated LY2109761, a TGF-β receptor inhibitor, affects scar tissue fibroblasts.
Purpose of the Study:
- To elucidate the mechanism by which LY2109761 affects keloid-derived fibroblasts.
- To investigate the role of Smad2/3 signaling and TGF-β1 in keloid development.
Main Methods:
- Replication of previous findings in keloid-derived fibroblasts.
- Assessment of LY2109761's effects on fibroblast apoptosis.
- Measurement of Smad2 and Smad3 phosphorylation.
- Quantification of TGF-β1 levels.
Main Results:
- LY2109761 promoted apoptosis in keloid fibroblasts.
- LY2109761 decreased the phosphorylation of Smad2 and Smad3.
- LY2109761 suppressed TGF-β1 levels.
Conclusions:
- The Smad2/3 signaling pathway and elevated TGF-β1 receptor expression positively regulate keloid development.
- LY2109761 and similar inhibitors represent potential therapeutic strategies for limiting excessive scarring.
